Editorial
Split Viewer
Blood Res 2013; 48(4):
Published online December 31, 2013
https://doi.org/10.5045/br.2013.48.4.235
© The Korean Society of Hematology
Attempts to treat patients with hemophilia, the "royal disease"
Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Lawrence, JS, Johnson, JB. The presence of a circulating anticoagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc, 1941;57;223-231.
- Darby, SC, Keeling, DM, Spooner, RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost, 2004;2;1047-1054.
- Kempton, CL, White, GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 2009;113;11-17.
- Goudemand, J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl, 1998;63;24-27.
- Hay, CR, DiMichele, DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 2012;119;1335-1344.
- Mannucci, PM. Getting rid of refractory hemophilia. Blood, 2012;119;1326-1327.
- Astermark, J, Donfield, SM, DiMichele, DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood, 2007;109;546-551.
- Ingerslev, J, Sorensen, B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol, 2011;155;256-262.
- Berntorp, E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia, 2009;15;3-10.
- Han, MH, Park, YS. Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience. Blood Res, 2013;48;282-286.
PDF
Standard view
Export citation
Share Article
Editorial
Blood Res 2013; 48(4): 235-236
Published online December 31, 2013 https://doi.org/10.5045/br.2013.48.4.235
Copyright © The Korean Society of Hematology.
Attempts to treat patients with hemophilia, the "royal disease"
Rojin Park, M.D.
Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Lawrence, JS, Johnson, JB. The presence of a circulating anticoagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc, 1941;57;223-231.
- Darby, SC, Keeling, DM, Spooner, RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost, 2004;2;1047-1054.
- Kempton, CL, White, GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 2009;113;11-17.
- Goudemand, J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl, 1998;63;24-27.
- Hay, CR, DiMichele, DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 2012;119;1335-1344.
- Mannucci, PM. Getting rid of refractory hemophilia. Blood, 2012;119;1326-1327.
- Astermark, J, Donfield, SM, DiMichele, DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood, 2007;109;546-551.
- Ingerslev, J, Sorensen, B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol, 2011;155;256-262.
- Berntorp, E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia, 2009;15;3-10.
- Han, MH, Park, YS. Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience. Blood Res, 2013;48;282-286.
Previous Article
